NCT02044354 2026-04-01
CABA-DOC
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Completed
Clinical Trials
40 trialsNCT06193486 2026-03-31
Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Recruiting
NCT06401980 2026-03-30
Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Swiss Cancer Institute
Phase 2 Recruiting
NCT07476001 2026-03-17
Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT04109729 2026-03-02
Rad2Nivo
University of Utah
Phase 1 Active not recruiting
NCT04754191 2026-02-12
ENCORE
University of Utah
Phase 2 Active not recruiting
NCT05570994 2026-01-08
177Lu-HTK03170 in mCRPC With PSMA Positive Disease
British Columbia Cancer Agency
Phase 1/2 Enrolling by invitation
NCT06866938 2026-01-06
ReaLuP
Hospices Civils de Lyon
Phase 2 Recruiting
NCT06568562 2025-12-09
PRO-XL
University of Utah
Phase 2 Recruiting
NCT06029998 2025-11-28
BORXPTEN
University of Utah
Phase 2 Recruiting
NCT06100705 2025-11-04
Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC
Yale University
Phase 2 Recruiting
NCT05613894 2025-10-31
CaboLu
University of Utah
Phase 1 Recruiting
NCT05603559 2025-10-03
177Lu-P17-087/177Lu-P17-088 in Patients With Metastatic Castration-resistant Prostate Cancer
Peking Union Medical College Hospital
Phase EARLY_PHASE1 Recruiting
NCT04158245 2025-09-22
18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies
Tulane University
Phase 2 Completed
NCT05544227 2025-07-23
Phase 1 Trial of SYNC-T - Immunotherapy for Advanced/Metastatic Castration-Resistant Prostate Cancer
Williams Cancer Foundation
Phase 1 Completed
NCT04253262 2025-05-04
A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer
Brown University
Phase 1/2 Active not recruiting
NCT06480110 2025-04-13
Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer
Rigshospitalet, Denmark
Phase 1/2 Recruiting
NCT05340374 2025-04-06
LuCAB
Peter MacCallum Cancer Centre, Australia
Phase 1/2 Active not recruiting
NCT06250244 2024-12-11
177Lu-LNC1011 in Patients with Metastatic Castration-resistant Prostate Cancer
Peking Union Medical College Hospital
Phase 1/2 Unknown
NCT05116579 2024-09-05
Circulating Tumor DNA (ctDNA) Monitoring in the Assessment and Prediction of the Efficacy of PARP Inhibitors (PARPi)
Sun Yat-sen University
Recruiting
NCT04629781 2024-08-01
Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in Patients With mCRPC
Swiss Cancer Institute
Phase 1 Terminated
NCT06529549 2024-07-31
Efficacy and Safety of Organoid-Based Drug Sensitivity Screening to Guide the Treatment of mCRPC Patients Progressed After First-line Treatment
Sun Yat-sen University
Recruiting
NCT05613738 2024-07-10
177Lu-PSMA-EB-01 in Patients With Metastatic Castration-resistant Prostate Cancer
Peking Union Medical College Hospital
Phase NA Recruiting
NCT03770455 2024-07-09
Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC
Tulane University
Phase 2 Terminated
NCT05762536 2024-06-27
DAROTAXEL
Erasmus Medical Center
Phase 2 Recruiting
NCT03835533 2024-04-12
PORTER
Parker Institute for Cancer Immunotherapy
Phase 1 Completed
NCT06242509 2024-02-05
AkkPRO
Assistance Publique - Hôpitaux de Paris
Unknown
NCT04000776 2023-08-28
3TMPO (Triple-Tracer Strategy Against Metastatic Prostate Cancer
Université de Sherbrooke
Completed
NCT05558956 2023-07-27
Total Body PET-CT Imaging of Prostate Cancer Using Illuccix
BAMF Health
Phase EARLY_PHASE1 Unknown
NCT05955209 2023-07-21
Clinical Study on the Efficacy and Safety of RC48-ADC in the Treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC)
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT04676607 2023-06-13
SHR7390 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Completed
NCT05823402 2023-05-03
SPECTacular
BAMF Health
Phase NA Unknown
NCT04879589 2023-04-28
Phase 1 Study of ATRS-2002 in Healthy Male Adults
Syneos Health
Phase 1 Withdrawn
NCT01942837 2022-10-24
Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT04237584 2022-10-07
ESCALATE
MANA RBM
Phase 3 Terminated
NCT03780075 2022-05-12
Lu177-EB-PSMA617 Radionuclide Treatment in Patients With Metastatic Castration-resistant Prostate Cancer
Peking Union Medical College Hospital
Phase 1 Unknown
NCT05327621 2022-04-14
Pamiparib in mCRPC With HRD or BRCA1/2 Mutation
Sun Yat-sen University
Phase 2 Unknown
NCT04586543 2020-10-14
Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma
University of Pecs
Phase 2 Unknown
NCT04225910 2020-01-13
Clinical Trial of Ac225-PSMA Radioligand Therapy of Metastatic Castration-resistant Prostate Cancer
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Phase EARLY_PHASE1 Unknown
NCT03403595 2018-01-18
177Lu-EB-PSMA617 in Patients With Metastatic Castration-resistant Prostate Cancer
Peking Union Medical College Hospital
Phase 1 Unknown